Transcode Therapeutics Inc
NASDAQ:RNAZ
Transcode Therapeutics Inc
Cash from Financing Activities
Transcode Therapeutics Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Transcode Therapeutics Inc
NASDAQ:RNAZ
|
Cash from Financing Activities
$15.9m
|
CAGR 3-Years
142%
|
CAGR 5-Years
99%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Transcode Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
15.9m
USD
Based on the financial report for Dec 31, 2023, Transcode Therapeutics Inc's Cash from Financing Activities amounts to 15.9m USD.
What is Transcode Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
99%
Over the last year, the Cash from Financing Activities growth was 158 993%. The average annual Cash from Financing Activities growth rates for Transcode Therapeutics Inc have been 142% over the past three years , 99% over the past five years .